Trending NewsTrending NewsNASDAQ:CORT Corcept Therapeutics (CORT) Stock Price, News & Analysis $110.29 -4.57 (-3.98%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$111.28 +0.99 (+0.89%) As of 09/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Corcept Therapeutics Stock (NASDAQ:CORT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corcept Therapeutics alerts:Sign Up Key Stats Today's Range$108.41▼$117.9050-Day Range$85.90▼$123.5752-Week Range$28.66▼$126.38Volume17.23 million shsAverage Volume847,143 shsMarket Capitalization$11.92 billionP/E Ratio262.60Dividend YieldN/APrice Target$138.17Consensus RatingModerate Buy Company Overview Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases. Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery. The company supports the product through commercial and medical services for healthcare providers and patients. The company is also developing relacorilant, a selective glucocorticoid receptor modulator, for potential use in Cushing’s syndrome and other conditions in which excess cortisol activity may contribute to disease. Corcept was founded in 1998 and is headquartered in Menlo Park, California. Its commercial operations are centered in the United States, while its clinical development programs may involve research sites and participants in multiple regions. Joseph K. Belanoff, M.D., a co-founder of the company, serves as chief executive officer.AI Generated. May Contain Errors. Read More Corcept Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreCORT MarketRank™: Corcept Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 75th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCorcept Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCorcept Therapeutics has a consensus price target of $138.17, representing about 25.3% upside from its current price of $110.29.Amount of Analyst CoverageCorcept Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Corcept Therapeutics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth87.10% Earnings GrowthEarnings for Corcept Therapeutics are expected to grow by 87.10% in the coming year, from $1.86 to $3.48 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 262.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.67.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 262.60, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 17.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corcept Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.96% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Corcept Therapeutics has recently decreased by 3.07%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.68 News SentimentCorcept Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Corcept Therapeutics this week, compared to 12 articles on an average week.Search InterestOnly 6 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,674,595.00 in company stock.Percentage Held by Insiders20.70% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corcept Therapeutics' insider trading history. Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CORT Stock News HeadlinesRoberto Wandenkolk Vieira Sells 296 Shares of Corcept Therapeutics (NASDAQ:CORT) StockSeptember 20 at 5:38 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Corcept Therapeutics (NASDAQ:CORT)September 20 at 1:56 AM | americanbankingnews.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.September 20 at 1:00 AM | Porter & Company (Ad)What is Zacks Research's Estimate for CORT Q3 Earnings?September 20 at 1:12 AM | americanbankingnews.comQ4 EPS Estimate for Corcept Therapeutics Raised by AnalystSeptember 19 at 1:13 AM | americanbankingnews.comInsider Selling: Corcept Therapeutics (NASDAQ:CORT) Director Sells $1,106,900.00 in StockSeptember 17 at 6:37 AM | insidertrades.comCorcept Therapeutics (NASDAQ:CORT) Insider Sean Maduck Sells 25,000 Shares of StockSeptember 4, 2026 | insidertrades.comInsider Selling: Corcept Therapeutics (NASDAQ:CORT) Director Sells $12,251,409.50 in StockAugust 21, 2026 | insidertrades.comSee More Headlines CORT Stock Analysis - Frequently Asked Questions How have CORT shares performed this year? Corcept Therapeutics' stock was trading at $34.80 on January 1st, 2026. Since then, CORT shares have increased by 216.9% and is now trading at $110.29. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings data on Wednesday, July, 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.34. The company's revenue was up 31.7% compared to the same quarter last year. Read the conference call transcript. Who are Corcept Therapeutics' major shareholders? Top institutional shareholders of Corcept Therapeutics include BlackRock Inc. (11.50%), Bank of New York Mellon Corp (0.52%), Bank of America Corp DE (0.30%) and Legal & General Group Plc (0.20%). Insiders that own company stock include Joseph K Belanoff, G Leonard Baker Jr, David L Mahoney, James N Wilson, Kimberly Park, Gary Charles Robb, Atabak Mokari, Sean Maduck, Joseph Douglas Lyon, William Guyer, Roberto Wandenkolk Vieira, Daniel N Swisher, Jr and Daniel N Swisher Jr. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corcept Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Intel (INTC) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings7/29/2026Today9/20/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CORT's financial health is in the Green zone, according to TradeSmith. CORT has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CORT CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees730Year Founded1998Price Target and Rating Average Price Target for Corcept Therapeutics$138.17 High Price Target$165.00 Low Price Target$50.00 Potential Upside/Downside+25.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$0.42 Trailing P/E Ratio262.60 Forward P/E Ratio59.30 P/E GrowthN/ANet Income$99.65 million Net Margins6.52% Pretax Margin3.17% Return on Equity8.26% Return on Assets6.45% Debt Debt-to-Equity RatioN/A Current Ratio2.86 Quick Ratio2.77 Sales & Book Value Annual Sales$761.41 million Price / Sales15.66 Cash Flow$0.90 per share Price / Cash Flow122.17 Book Value$6.16 per share Price / Book17.90Miscellaneous Outstanding Shares108,100,000Free Float85,722,000Market Cap$11.92 billion OptionableOptionable Beta0.45 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CORT) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
